Literature DB >> 30670421

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Paolo Denti1, Anneke C Hesseling2, Anthony J Garcia-Prats3, Susan E Purchase2, Muhammad Osman2, Heather R Draper2, H Simon Schaaf2, Lubbe Wiesner1.   

Abstract

This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (n = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult tablets had 41% lower bioavailability than the novel dispersible tablets, resulting in much higher exposures with the dispersible tablets with the same dose.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  bioavailability; children; dispersible tablets; formulation; levofloxacin; multidrug-resistant tuberculosis; pharmacokinetics

Mesh：

Substances：

Year:  2019        PMID： 30670421      PMCID： PMC6437514          DOI： 10.1128/AAC.01865-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.

Authors:  Sundari R Mase; John A Jereb; Daniel Gonzalez; Fatma Martin; Charles L Daley; Dorina Fred; Ann M Loeffler; Lakshmy R Menon; Sapna Bamrah Morris; Richard Brostrom; Terence Chorba; Charles A Peloquin
Journal:  Pediatr Infect Dis J       Date:  2016-04       Impact factor: 2.129

2.  Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 3.  The role of formulation on the pharmacokinetics of antiretroviral drugs.

Authors:  Diane E T Bastiaans; Tim R Cressey; Herman Vromans; David M Burger
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-05-30       Impact factor: 4.481

4.  Levofloxacin pharmacokinetics in children.

Authors:  Shuchean Chien; Thomas G Wells; Jeffrey L Blumer; Gregory L Kearns; John S Bradley; Joseph A Bocchini; Jaya Natarajan; Samuel Maldonado; Gary J Noel
Journal:  J Clin Pharmacol       Date:  2005-02       Impact factor: 3.126

5.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

6.  Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.

Authors:  Gary J Noel; John S Bradley; Ralph E Kauffman; Ciaran M Duffy; Peter G Gerbino; Adriano Arguedas; Partha Bagchi; Dainius A Balis; Jeffrey L Blumer
Journal:  Pediatr Infect Dis J       Date:  2007-10       Impact factor: 2.129

7.  Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

Authors:  H McIlleron; H Hundt; W Smythe; A Bekker; J Winckler; L van der Laan; P Smith; H J Zar; A C Hesseling; G Maartens; L Wiesner; A van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

8.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191
  8 in total
  4 in total

1.  Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.

Authors:  Hamidah Hussain; Courtney M Yuen; Amyn A Malik; Meredith B Brooks; Sara Siddiqui; Junaid Fuad; Charles A Peloquin; Farhana Amanullah; Maria Jaswal; Mercedes C Becerra
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.

Authors:  Pauline Howell; Jay Achar; G Khai Lin Huang; Andrei Mariandyshev; H Simon Schaaf; Anthony J Garcia-Prats
Journal:  Pathogens       Date:  2022-03-23

3.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

4.  Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.

Authors:  Henrik Bjugård Nyberg; Heather R Draper; Anthony J Garcia-Prats; Stephanie Thee; Adrie Bekker; Heather J Zar; Andrew C Hooker; H Simon Schaaf; Helen McIlleron; Anneke C Hesseling; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.938
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.